Link Immunotherapeutics (CT-95) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Link Immunotherapeutics (CT-95) General Information

Description

A medical product intended to cure cancer cells.

Contact Information

Formerly Known As
LNK101
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Seattle, WA
  • United States
Primary Industry
Buildings and Property
Other Industries
Biotechnology
Acquirer
Context Therapeutics
Corporate Office
  • Seattle, WA
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Link Immunotherapeutics (CT-95) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Link Immunotherapeutics (CT-95)‘s full profile, request access.

Request a free trial

Link Immunotherapeutics (CT-95) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Link Immunotherapeutics (CT-95)‘s full profile, request access.

Request a free trial

Link Immunotherapeutics (CT-95) FAQs

  • Where is Link Immunotherapeutics (CT-95) headquartered?

    Link Immunotherapeutics (CT-95) is headquartered in Seattle, WA.

  • What industry is Link Immunotherapeutics (CT-95) in?

    Link Immunotherapeutics (CT-95)’s primary industry is Buildings and Property.

  • Is Link Immunotherapeutics (CT-95) a private or public company?

    Link Immunotherapeutics (CT-95) is a Private company.

  • What is the current valuation of Link Immunotherapeutics (CT-95)?

    The current valuation of Link Immunotherapeutics (CT-95) is .

  • What is Link Immunotherapeutics (CT-95)’s current revenue?

    The current revenue for Link Immunotherapeutics (CT-95) is .

  • Who are Link Immunotherapeutics (CT-95)’s investors?

    Link Immunotherapeutics has invested in Link Immunotherapeutics (CT-95).

  • When was Link Immunotherapeutics (CT-95) acquired?

    Link Immunotherapeutics (CT-95) was acquired on 09-Jul-2024.

  • Who acquired Link Immunotherapeutics (CT-95)?

    Link Immunotherapeutics (CT-95) was acquired by Context Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process